These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 34756766)

  • 1. Sex-related differences in the clinical characteristics of wild-type transthyretin amyloidosis cardiomyopathy.
    Takashio S; Yamada T; Nishi M; Morioka M; Fujiyama A; Nakashima N; Hirakawa K; Hanatani S; Usuku H; Yamamoto E; Ueda M; Matsushita K; Tsujita K
    J Cardiol; 2022 Jan; 79(1):50-57. PubMed ID: 34756766
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Integrated diagnostic approach to wild-type transthyretin cardiac amyloidosis with the use of high-sensitivity cardiac troponin T measurement and
    Ochi Y; Kubo T; Nakashima Y; Baba Y; Hirota T; Yamasaki N; Yamashita T; Ueda M; Ando Y; Kitaoka H
    J Cardiol; 2020 Jan; 75(1):12-19. PubMed ID: 31324572
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inverse correlation between age of onset and myocardial amyloid deposition quantified by
    Kanaya H; Shiraishi S; Ogasawara K; Iwashita K; Sakamoto F; Takashio S; Mikami Y; Tsujita K; Hirai T
    Ann Nucl Med; 2024 Sep; 38(9):744-753. PubMed ID: 38874878
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction.
    González-López E; Gallego-Delgado M; Guzzo-Merello G; de Haro-Del Moral FJ; Cobo-Marcos M; Robles C; Bornstein B; Salas C; Lara-Pezzi E; Alonso-Pulpon L; Garcia-Pavia P
    Eur Heart J; 2015 Oct; 36(38):2585-94. PubMed ID: 26224076
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transthyretin amyloid cardiomyopathy among patients with heart failure and preserved ejection fraction: the AMY score.
    Gioia G; Schrutka L; Jozwiak-Nozdrzykowska J; Kresoja KP; Gunold H; Klingel K; Thiele H; Bonderman D; Lurz P; Rommel KP
    ESC Heart Fail; 2024 Aug; 11(4):2172-2181. PubMed ID: 38613409
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Wild-type transthyretin cardiac amyloidosis is not rare in elderly subjects: the CATCH screening study.
    Aimo A; Vergaro G; Castiglione V; Fabiani I; Barison A; Gentile F; Ferrari Chen YF; Giorgetti A; Genovesi D; Buda G; Franzini M; Piepoli M; Moscardini S; Rapezzi C; Fontana M; Passino C; Emdin M
    Eur J Prev Cardiol; 2024 Aug; 31(11):1410-1417. PubMed ID: 38456769
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Non-invasive detection and differentiation of cardiac amyloidosis using
    Takasone K; Katoh N; Takahashi Y; Abe R; Ezawa N; Yoshinaga T; Yanagisawa S; Yazaki M; Oguchi K; Koyama J; Sekijima Y
    Amyloid; 2020 Dec; 27(4):266-274. PubMed ID: 32722948
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reduced trans-mitral A-wave velocity predicts the presence of wild-type transthyretin amyloidosis in elderly patients with left ventricular hypertrophy.
    Yamamura S; Izumiya Y; Ishida T; Onoue Y; Kimura Y; Hanatani S; Araki S; Fujisue K; Sueta D; Kanazawa H; Takashio S; Usuku H; Sugamura K; Sakamoto K; Yamamoto E; Yamamuro M; Yasuda H; Kojima S; Kaikita K; Hokimoto S; Ogawa H; Tsujita K
    Heart Vessels; 2017 Jun; 32(6):708-713. PubMed ID: 27882404
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Usefulness of quantitative
    Ogasawara K; Shiraishi S; Tsuda N; Sakamoto F; Oda S; Takashio S; Tsujita K; Hirai T
    Jpn J Radiol; 2022 May; 40(5):508-517. PubMed ID: 34973114
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic value of tafamidis in patients with wild-type transthyretin amyloidosis (ATTRwt) with cardiomyopathy based on cardiovascular magnetic resonance (CMR) imaging.
    Chamling B; Bietenbeck M; Korthals D; Drakos S; Vehof V; Stalling P; Meier C; Yilmaz A
    Clin Res Cardiol; 2023 Mar; 112(3):353-362. PubMed ID: 35666277
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Left ventricular structure and function in transthyretin-related versus light-chain cardiac amyloidosis.
    Quarta CC; Solomon SD; Uraizee I; Kruger J; Longhi S; Ferlito M; Gagliardi C; Milandri A; Rapezzi C; Falk RH
    Circulation; 2014 May; 129(18):1840-9. PubMed ID: 24563469
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Extracardiac Biopsy Sensitivity in Transthyretin Amyloidosis Cardiomyopathy Patients With Positive
    Nishi M; Takashio S; Morioka M; Fujiyama A; Nakashima N; Hirakawa K; Hanatani S; Usuku H; Yamamoto E; Kidoh M; Oda S; Gushima R; Matsushita K; Fukushima S; Ueda M; Tsujita K
    Circ J; 2022 Jun; 86(7):1113-1120. PubMed ID: 35599006
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diflunisal treatment is associated with improved survival for patients with early stage wild-type transthyretin (ATTR) amyloid cardiomyopathy: the Boston University Amyloidosis Center experience.
    Siddiqi OK; Mints YY; Berk JL; Connors L; Doros G; Gopal DM; Kataria S; Lohrmann G; Pipilas AR; Ruberg FL
    Amyloid; 2022 Jun; 29(2):71-78. PubMed ID: 35083944
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transthyretin Cardiac Amyloidosis as Diagnosed by 99mTc-PYP Scanning in Patients with Acute Heart Failure and Preserved Ejection Fraction.
    Lo Presti S; Horvath SA; Mihos CG; Rajadhyaksha C; McCloskey V; Santana O
    Crit Pathw Cardiol; 2019 Dec; 18(4):195-199. PubMed ID: 31725511
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Association of Cardiac Biomarkers, the Intensity of Tc99 Pyrophosphate Uptake, and Survival in Patients Evaluated for Transthyretin Cardiac Amyloidosis in the Early Therapeutics Era.
    Martyn T; Saef J; Hussain M; Ives L; Kiang A; Estep JD; Collier P; Starling RC; Cremer PC; Tang WHW; Hanna M; Jaber WA
    J Card Fail; 2022 Oct; 28(10):1509-1518. PubMed ID: 35843490
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiac sympathetic denervation in wild-type transthyretin amyloidosis.
    Gimelli A; Aimo A; Vergaro G; Genovesi D; Santonato V; Kusch A; Emdin M; Marzullo P
    Amyloid; 2020 Dec; 27(4):237-243. PubMed ID: 32441155
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Temporal Trends in Diagnostic Testing Patterns for Wild-Type Transthyretin Amyloid Cardiomyopathy in the Medicare Fee-for-Service Population.
    Bourque JM; Schepart A; Bhambri R; Castaño A; O'Brien A; Chen Y; Prasad S; Roy A; Grodin JL
    Am J Cardiol; 2022 Mar; 167():98-103. PubMed ID: 35022130
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Gluteus Medius Muscle Biopsy to Confirm Amyloid Transthyretin Deposition in Wild-type Transthyretin Cardiac Amyloidosis: A Report of Two Cases.
    Takahashi K; Iwamura T; Hiratsuka Y; Sasaki D; Yamamura N; Ueda M; Morioka H; Yoshino M; Enomoto D; Uemura S; Okura T; Sakaue T; Ikeda S
    Intern Med; 2024 Jun; 63(11):1575-1584. PubMed ID: 37899242
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical characteristics of wild-type transthyretin cardiac amyloidosis: disproving myths.
    González-López E; Gagliardi C; Dominguez F; Quarta CC; de Haro-Del Moral FJ; Milandri A; Salas C; Cinelli M; Cobo-Marcos M; Lorenzini M; Lara-Pezzi E; Foffi S; Alonso-Pulpon L; Rapezzi C; Garcia-Pavia P
    Eur Heart J; 2017 Jun; 38(24):1895-1904. PubMed ID: 28329248
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Native T1 and Extracellular Volume in Transthyretin Amyloidosis.
    Martinez-Naharro A; Kotecha T; Norrington K; Boldrini M; Rezk T; Quarta C; Treibel TA; Whelan CJ; Knight DS; Kellman P; Ruberg FL; Gillmore JD; Moon JC; Hawkins PN; Fontana M
    JACC Cardiovasc Imaging; 2019 May; 12(5):810-819. PubMed ID: 29550324
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.